ArticleAmerican journal of translational research2023
Cell division cycle associated 8 promotes the growth and inhibits the apoptosis of endometrial cancer cells by regulating cell cycle and P53/Rb signaling pathway.
Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Data-Driven Discovery of a Key Regulator Cyclin A2 as a Promising Therapeutic Target in Hormone-Sensitive Cancers.Molecular biotechnology · 2026Article
- SIM2, associated with clinicopathologic features, promotes the malignant biological behaviors of endometrial carcinoma cells.BMC cancer · 2025Article
- Article
- Overexpression of CDCA8 predicts poor prognosis and drug insensitivity in lung adenocarcinoma.BMC medical genomics · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCell division cycle associated 8 (CDCA8) is over-expressed in a variety of tumors and associated with tumor progression. Nevertheless, the role of CDCA8 in endometrial cancer (EC) is unclear. Therefore, this study aimed to assess the role and mechanism of CDCA8 in EC.
methodsImmunohistochemical staining was used to evaluate CDCA8 expression in EC, and its relationship with clinicopathology was analyzed. CDCA8 was knocked down or over-expressed to study its effects on cell biological behaviors. Furthermore, the feasible mechanisms of CDCA8 were examined by Western blot.
resultsCDCA8 was significantly upregulated in EC tissue (P<0.05) and related to worse tumor grade, Figo stage, tumor (T) stage, and deep myometrial invasion (P<0.05). CDCA8 knockdown inhibited EC cell activities, promoted apoptosis and induced cell cycle arrest (P<0.05), which were reversed by CDCA8 over-expression (P<0.05). Besides, CDCA8 knockdown inhibited the growth of xenograft tumors in nude mice (P<0.05). Furthermore, CDCA8 may affect cell cycle and P53/Rb signaling pathway in EC cells.
conclusionCDCA8 plays a role in the pathogenesis of EC and may be a target for EC treatment.
Indexed as
Identifiers
37434858PMC10331643What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.